Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, 1 and Merck and Co., Inc., West Point, Pennsylvania 2
|
|
- Gabriella Tucker
- 5 years ago
- Views:
Transcription
1 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 1997, p Vol. 41, No /97/$ Copyright 1997, American Society for Microbiology Comparative In Vitro Antimicrobial Susceptibilities of Nosocomial Isolates of Acinetobacter baumannii and Synergistic Activities of Nine Antimicrobial Combinations MARISA B. MARQUES, 1 ENEIDA S. BROOKINGS, 1 STEPHEN A. MOSER, 1 PHILLIP B. SONKE, 2 AND KEN B. WAITES 1 * Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, 1 and Merck and Co., Inc., West Point, Pennsylvania 2 Received 19 August 1996/Returned for modification 18 November 1996/Accepted 14 February 1997 The in vitro susceptibilities of 69 nosocomial Acinetobacter isolates were determined by the broth microdilution method. Fourteen (20%) isolates were resistant to at least two aminoglycosides and two extendedspectrum penicillins. Nine antimicrobial combinations were then tested for synergy against these 14 isolates by checkerboard titration: imipenem with ciprofloxacin, amikacin, and tobramycin and ampicillin-sulbactam, piperacillin-tazobactam, and ticarcillin-clavulanate with amikacin and tobramycin. Synergy was detected with one or more antimicrobial combinations against 9 of 14 (64%) isolates, partial synergy was detected with one or more combinations against all 14 isolates, and an additive effect alone was observed with two different combinations against two isolates. No antagonism was detected with any combination. Imipenem plus either amikacin or tobramycin resulted in a synergistic or partial synergistic response against all 14 isolates. Specific combinations showing synergy against A. baumannii isolates were imipenem with tobramycin (four isolates), imipenem with amikacin (three isolates), ampicillin-sulbactam with tobramycin (six isolates), ampicillinsulbactam with amikacin (three isolates), and ticarcillin-clavulanate with tobramycin (one isolate). Genotyping by randomly amplified polymorphic DNA analysis showed that 9 of the 14 isolates were of one strain, 4 isolates were of a second strain, and the remaining isolate was of a different strain. Eight of 14 (57%) patients infected with resistant A. baumannii isolates died. Only 3 of 14 patients had received a therapeutic regimen which was tested for synergy. Clinical studies are needed to determine the significance of these findings. Acinetobacter species are emerging as a major cause of nosocomial infections, particularly in intensive care and burn units, where antimicrobial use is greatest (29). Outbreaks of infections caused by multiple drug-resistant (MDR) Acinetobacter spp. have been widely reported (3, 10, 31, 33). Our institution experienced such an outbreak in the medical intensive care unit, with several fatalities, despite aggressive treatment (20). Concurrently, MDR Acinetobacter spp. were recovered from patients in other areas of the hospital. Due to the life-threatening potential of such infections, empiric treatment with broad-spectrum antimicrobial agents is mandatory while awaiting organism identification and in vitro susceptibility test results (1). However, increasing antimicrobial resistance in Acinetobacter spp. has effectively eliminated many treatment alternatives, raising concerns about optimum therapeutic regimens (9, 11, 15, 17, 18, 27, 30, 31, 34). Combination therapy including imipenem or another -lactam with an aminoglycoside such as amikacin has been recommended for empiric treatment when infection with an Acinetobacter sp. is suspected (1), but few studies have examined whether there is synergism between these or newer agents, including extended-spectrum penicillins, against these organisms. Historically, evaluations of interactions between antimicrobial agents against bacteria have been most valuable for endocarditis and infections in neutropenic patients (14, 19). However, for emerging MDR organisms, when there is a lack of prior information on the effectiveness of two agents combined, * Corresponding author. Mailing address: Department of Pathology WP 230, University of Alabama at Birmingham, 618 South 18th St., Birmingham, AL Phone: (205) Fax: (205) or in the case of a poor therapeutic response, such investigations may also be useful in helping to guide therapy. Checkerboard titration, the technique used most often to assess antimicrobial combinations in vitro (16), was chosen to evaluate the inhibitory effects of nine combinations of antimicrobial agents against 14 MDR isolates of Acinetobacter baumannii. MATERIALS AND METHODS Bacteria. Sixty-nine Acinetobacter isolates obtained from blood, lung tissue, sputum, tracheal aspirates, urine, and wounds over a 6-month period in 1994 were stored at 70 C. Organisms were identified and antimicrobial susceptibilities were determined initially by using the MicroScan WalkAway 96 instrument (Dade MicroScan, West Sacramento, Calif.). Susceptibilities were redetermined by using frozen microtiter plates (PML Microbiologicals, Tualatin, Oreg.) to allow for the inclusion of additional antimicrobial agents. Prior to testing, the organisms were passaged twice onto Trypticase soy agar (TSA) containing 5% sheep blood (BBL, Cockeysville, Md.) and were incubated overnight. Suspensions in saline with a turbidity equivalent to that of a 0.5 McFarland standard were prepared, diluted, and inoculated into microtiter plates. The final inoculum density was to CFU/ml. The plates were incubated for 20 to 24 h and the MICs were read. The 12 antimicrobial agents tested were imipenem, ampicillin-sulbactam (A/S), piperacillin, piperacillin-tazobactam (P/T), ticarcillin-clavulanate (T/C), ciprofloxacin, ofloxacin, amikacin, gentamicin, tobramycin, rifampin, and trimethoprim-sulfamethoxazole. Fourteen isolates which were resistant to at least two aminoglycosides and two extended-spectrum penicillins were selected for use in synergy tests. Antimicrobial agents used in synergy tests. Standard powders of the following antimicrobial agents for laboratory use were obtained from their respective manufacturers: ciprofloxacin (Miles Inc., West Haven, Conn.), amikacin (Bristol- Myers Squibb Co., Princeton, N.J.), piperacillin and tazobactam (Wyeth-Ayerst Laboratories, Philadelphia, Pa.), ampicillin and sulbactam (Roerig Division, Pfizer Inc., New York, N.Y.), imipenem (Merck and Co., Inc., West Point, Pa.), and ticarcillin and clavulanate (SmithKline Beecham Pharmaceuticals, Philadelphia, Pa.). Stock solutions of ciprofloxacin, amikacin, piperacillin, tazobactam, ampicillin, and sulbactam were prepared according to published standards (23) and were frozen at 70 C until use. Stock solutions of imipenem, ticarcillin, and clavulanate were prepared fresh on the day of each assay. Tobramycin (Eli Lilly & Co., Indianapolis, Ind.) was obtained already in solution (10 mg/ml). The 881
2 882 MARQUES ET AL. ANTIMICROB. AGENTS CHEMOTHER. TABLE 1. Antimicrobial agents tested for synergy against 14 A. baumannii isolates Antimicrobial agent Concn tested ( g/ml) Peak concn in plasma ( g/ml) a Dose b Imipenem mg A/S 0.5/ / / g/1.0 g P/T 0.5/4 128/4 298/ g/0.5 g T/C 4/2 256/2 324/8 3.0 g/0.1 g Ciprofloxacin mg Amikacin mg/kg Tobramycin mg/kg a Data are from a previous publication (24). b The doses listed are those which are expected to produce concentrations in plasma in the indicated ranges (24). antimicrobial agents were stored according to the manufacturer s recommendations prior to dilution in cation-adjusted Mueller-Hinton broth (BBL). The following antimicrobial combinations were tested: imipenem with ciprofloxacin, amikacin, and tobramycin and A/S, P/T, and T/C with amikacin and tobramycin. For T/C and P/T, clavulanic acid and tazobactam were tested at fixed concentrations of 2 and 4 g/ml, respectively, while A/S was tested with ampicillin and sulbactam at a fixed 2:1 ratio (Table 1). Test methodology. Fourteen MDR isolates were further identified as A. baumannii (4 6). Synergy tests were performed in a 96-well microtiter plate (Dynatech Laboratories, Chantilly, Va.) containing two antimicrobial agents in twofold dilutions dispensed in a checkerboard fashion on the day of the assay. Each well contained 0.1 ml of individual antimicrobial combinations or broth controls. Suspensions with turbidities equivalent to that of a 0.5 McFarland standard were prepared to yield a final inoculum of to CFU/ml. The plates were incubated for 20 to 24 h, and the MICs were read. Growth and sterility controls were included in each plate. To check for purity, TSA was inoculated from the growth control well, and for inoculum verification, serial dilutions were plated onto TSA. Quality control strains were Pseudomonas aeruginosa ATCC 27853, Escherichia coli ATCC 25922, and E. coli ATCC Reproducibility of MICs. The MICs of each drug for the 14 MDR A. baumannii isolates were determined twice with MicroScan Overnight Neg Combo panels, once with frozen MIC panels read manually, and one or more times by the broth microdilution method in the synergy assays. Synergy tests were considered valid if the measured MICs of the individual antimicrobial agents were within 1 dilution of the values obtained in the original determinations of the MICs of the drugs tested alone. Interpretation of synergy tests. For the first clear well in each row of the microtiter plate containing both antimicrobial agents, the fractional inhibitory concentration (FIC) of each agent was calculated as follows (16): FIC of drug A (FIC A ) MIC of drug A in combination/mic of drug A alone, and the FIC of drug B (FIC B ) MIC of drug B in combination/mic of drug B alone. If the MIC of any agent alone occurred at the lowest or highest concentrations tested, the FIC was considered not determinable and synergy could not be assessed. The summation of both FICs ( FIC) in each well ( FIC FIC A FIC B ) was used Isolate TABLE 2. MICs of seven antimicrobial agents tested for 14 isolates of A. baumannii MIC ( g/ml) a IMI AMK TOB A/S P/T T/C CIP /8 128/4 256/ /8 128/4 256/ /4 128/4 256/ /4 128/4 256/ /4 128/4 256/ /4 128/4 256/ /8 128/4 256/ /1 0.5/4 256/ /8 128/4 256/ /8 128/4 256/ /2 128/8 256/ /2 16/4 256/ /16 128/4 256/ /4 128/4 256/8 32 a Abbreviations: IMI, imipenem; AMK, amikacin; TOB, tobramycin; CIP, ciprofloxacin. TABLE 3. Combinations of antimicrobial agents which resulted in synergistic, partially synergistic, or additive reactions Drug combination (concn [ g/ml]) No. of isolates a Syn Part syn Addit IMI AMK Total b Total b / / / / / / / / / / / / / Total b / / / / / / / Total b ( g/ml) 16/ / / / / Total b / / / Total b P/T TOB 8/ / Total b a Abbreviations: Syn, synergistic; Part syn, partially synergistic; Addit, additive. b Total number of isolates (some were inhibited by more than one concentration of the same combination).
3 VOL. 41, 1997 ANTIMICROBIAL SYNERGISM AGAINST A. BAUMANNII 883 TABLE 4. Biotypes, genotypes, and synergistic interactions for 14 A. baumannii isolates a Isolate no. Hospital unit Biotype DNA pattern Synergy Partial synergy 1 MICU 9 A IMI AMK A/S AUK 2 MICU 9 A IMI AMK 3 MICU 9 A IMI AMK 4 Non-ICU 9 A IMI AMK Additivity 5 Burn 9 A IMI AMK 6 Burn 9 A IMI AMK 7 SICU 9 A IMI AMK 8 MICU 1 B IMI AMK 9 Non-ICU 8 A IMI AMK 10 HTICU 9 A IMI AMK 11 MICU 1 B IMI AMK 12 SICU 9 Other IMI AMK P/T TOB 13 MICU 1 B IMI AMK 14 Non-ICU 1 B IMI AMK a Abbreviations: MICU, medical intensive care unit; SICU, surgical intensive care unit; HTICU, heart transplant intensive care unit; AMK, amikacin; IMI, imipenem; TOB, tobramycin. to classify the combination of antimicrobial agents at the given concentrations as synergistic ( FIC, 0.5), partially synergistic ( FIC, 0.5 and 1.0), additive ( FIC, 1.0), indifferent ( FIC, 1 and 4), or antagonistic ( FIC, 4). Synergistic, partially synergistic, or additive interactions were reported only if they occurred within the range of therapeutic concentrations achievable in human plasma, as indicated in Table 1. Furthermore, partial synergy was reported only if no synergy was detected at any clinically relevant concentration of that antimicrobial combination and additivity was reported only if no synergy or partial synergy was detected (see Tables 3 and 4). The peak concentration in plasma was used to define the upper limit of clinically relevant antimicrobial concentrations at which synergy occurred (13, 22, 25, 26, 28, 32). Although this is not the most important parameter for assessment of the clinical efficacy of -lactams, it is not appropriate to consider drug concentrations above their peak concentrations achievable in human plasma. Biotyping and DNA analysis. The 14 MDR isolates of A. baumannii were biotyped as described previously (4 6). Randomly amplified polymorphic DNA pattern analysis (RAPD) with four random primers was used to determine genotypes. Organism suspensions in saline subcultured onto TSA were centrifuged, and the pellet was resuspended in extraction buffer (35). The suspension was heated in a boiling water bath, extracted twice with phenol-chloroform and once with chloroform, and precipitated with ethanol. The absorbance of the recovered DNA was measured to assess its concentration and purity. PCR was performed by using 200 ng of DNA as a template and four separate primers (35) and Stoffel DNA polymerase in a model 480 thermocycler (Perkin-Elmer, Norwalk, Conn.) under the following conditions: 95 C for 3 min and 40 cycles of 95 C for 1 min, 37 C for 1 min, and 72 C for 8 min. The reaction mixtures were analyzed by electrophoresis on a 2% agarose gel, and the bands were visualized following staining with ethidium bromide. Patient outcomes. Clinical and treatment data were obtained by review of the patients medical records. RESULTS Antimicrobial susceptibilities. Only four drugs showed activity against the 14 MDR A. baumannii isolates. All isolates were susceptible to imipenem, eight (57%) were susceptible to A/S, three (21%) were susceptible to amikacin, and two (14%) were susceptible to P/T (23). The MICs obtained during checkerboard titrations of each of the seven antimicrobial agents tested alone are indicated in Table 2. Synergy tests. The synergistic, partially synergistic, or additive effects of nine antimicrobial combinations are indicated in Tables 3 and 4. Synergy was detected with one or more antimicrobial combinations against nine isolates. Partial synergy was detected with one or more antimicrobial combinations against all 14 isolates. Additivity with one or more antimicrobial combinations was detected against eight isolates. However, additivity in the absence of either synergy or partial synergy was detected against only two isolates, with one different combination showing additivity against each isolate. No antagonism was detected. Except for the specific combinations mentioned below, all others were indifferent. Imipenem with amikacin showed synergy against three isolates and partial synergy against 11 isolates, whereas imipenem with tobramycin showed synergy against 4 isolates and partial synergy against 9 isolates. A/S with amikacin showed synergy against three isolates and partial synergy against eight isolates. A/S with tobramycin showed synergy against six isolates and partial synergy against seven isolates. An additive effect alone was observed for A/S with amikacin against one isolate. T/C with tobramycin showed synergy against one isolate but showed no synergy with amikacin. There was partial synergy for T/C with amikacin and tobramycin, against five and four isolates, respectively. T/C with tobramycin was additive against one isolate. The MICs of T/C exceeded the highest concentration tested for 5 of 14 isolates, so that no interpretation was possible (Table 2). Interpretation of synergy tests for P/T and ciprofloxacin was more problematic since the MICs exceeded the highest concentration tested for all 14 isolates in the case of ciprofloxacin and for 12 isolates in the case of P/T. For another isolate the MIC was less than the lowest concentration of P/T tested. Against the single isolate for which data were interpretable, P/T with tobramycin showed partial synergy. Even though the FIC could not be calculated, the MICs of both ciprofloxacin and P/T in the combinations tested remained in the resistant
4 884 MARQUES ET AL. ANTIMICROB. AGENTS CHEMOTHER. TABLE 5. Patient characteristics and outcomes Patient no. Age (yr)/ gender Diagnoses Hospital day of first positive culture range, making it unlikely that these agents would have therapeutic value. In addition, for ciprofloxacin, testing of higher concentrations would have been nonproductive since the levels achievable in human plasma would have been greatly exceeded (24). Correlation between genotype and synergy. Table 4 presents the results of biotyping and DNA analysis and the synergistic configurations for all 14 isolates. Nine isolates were classified as biotype 9, four were classified as biotype 1, and one was classified as biotype 8. Nine isolates had similar DNA types according to RAPD data (pattern A), with eight of nine isolates designated as biotype 9. This RAPD pattern was also observed for the isolate classified as biotype 8. The four isolates classified as biotype 1 all belonged to a second RAPD pattern (pattern B). A single isolate was shown to be distinct from isolates of both patterns A and B, but it was classifiable as biotype 9. There was no correlation between the relatedness of the isolates and the response to any antimicrobial combination. Patient outcomes. As indicated in Table 5, 8 of 14 people (57%) with A. baumannii infection died; 5 patients died within a few days of detection of the organism. Among seven patients with bacteremia, only one (14%) (patient 12) survived. Only three patients (patients 8, 12, and 13) received combinations of the antimicrobial agents which were tested. Patient 8 received treatment with imipenem and amikacin, a combination which showed synergy against the organism isolated from the respiratory tract. The patient died several weeks later of unrelated complications. Patient 12, a survivor, received amikacin and imipenem, a combination shown to be partially synergistic against the organism recovered from blood. Patient 13 was treated with ciprofloxacin and piperacillin, in addition to imipenem, but died several weeks after the infection due to unrelated factors. DISCUSSION Empiric therapy for nosocomial infections must include broad-spectrum agents expected to cover the most likely organisms according to historical institutional susceptibilities. Body site(s) of MDR A. baumanii Treatment Outcome (hospital day) 1 58/male Sepsis, pneumonia 1st Blood, a CSF, b tracheal aspirate Piperacillin, tobramycin, Died (7th) imipenem, gentamicin 2 58/female Sepsis 18th Blood, a postmortem blood and lung Imipenem Died (19th) 3 55/female Respiratory failure 5th Postmortem blood a and lung Piperacillin, gentamicin Died (5th) 4 69/male Renal and heart failure 56th Urine None Survived 5 55/male Burns 90th Tracheal aspirate Imipenem Survived 6 46/female Burns 50th Blood, a sputum Piperacillin, tobramycin Died (61st) 7 79/female Cholecystitis 25th Hand Imipenem, gentamicin Survived 8 76/male Pneumonia, respiratory 22nd Tracheal aspirate, a sputum Imipenem, amikacin, Died (83rd) failure ceftazidime 9 43/female Hip fracture 5th Hip Amikacin Survived 10 54/male Sepsis, pneumonia 61st Bronchoalveolar lavage fluid, Ceftazidime, gentamicin Died (63rd) postmortem lung and blood 11 52/female Diabetes, sepsis 33rd Blood, a tracheal aspirate, leg wound Ceftazidime, gentamicin, Died (35th) imipenem 12 23/male Burns 17th Blood, a chest wound Amikacin, imipenem Survived 13 64/female Diabetes, respiratory 101st Leg wound Ciprofloxacin, piperacillin, Died (153th) failure imipenem 14 34/male Hand injury 6th Finger Debridement, cefazolin, gentamicin Survived a Source of organism tested for synergy in patients infected with multiple MDR A. baumanii isolates. b CSF, cerebrospinal fluid. Toxicity often limits the ability to increase doses of individual agents to achieve concentrations which might effectively eradicate organisms from patients with potentially life-threatening systemic infections. Therefore, severe infections, particularly in debilitated hosts, require aggressive treatment, usually involving at least two antimicrobial agents (1). Combinations of agents that exhibit synergy, partial synergy, or even additive activity could potentially reduce toxicity and improve outcomes for patients with difficult-to-treat infections. In studies of gramnegative bacilli, combinations of a -lactam and amikacin which were synergistic in vitro have been associated with significantly better outcomes than those achieved with nonsynergistic regimens (19). The presence or absence of synergy may also be a significant factor related to outcome for patients with neutropenia, shock, and other underlying conditions (19). A recent report showed synergy with imipenem and both amikacin and tobramycin against several isolates among a group of 25 MDR A. baumannii isolates (21). Combinations of imipenem plus amikacin and P/T plus amikacin have been shown to be more rapidly bactericidal against MDR A. baumannii than imipenem plus sulbactam and P/T plus sulbactam (7). Chang et al. (8) found that imipenem plus amikacin demonstrated synergy against 36% of 22 isolates of A. baumannii causing bacteremia and partial synergy against 50% of the isolates, whereas in this study the values for this combination were 21 and 79%, respectively. In their study the organisms were much more susceptible overall than those in our study. Those investigators also detected a synergistic bactericidal effect using time-kill curves and concluded that imipenem plus amikacin was the best choice among the four combinations tested (8). In our study, synergy or partial synergy was also detected for combinations of A/S, T/C, P/T, and aminoglycosides within therapeutic concentrations in plasma, even though one or both agents were inactive when they were tested alone. Tobramycin had no activity alone against MDR A. baumannii isolates, but synergy and/or partial synergy with other agents was detected
5 VOL. 41, 1997 ANTIMICROBIAL SYNERGISM AGAINST A. BAUMANNII 885 against several isolates, suggesting its potential as an alternative to amikacin. Among the three -lactam -lactamase inhibitor combinations tested, only A/S demonstrated substantial activity alone or synergistically with aminoglycosides. This observation is consistent with the experience of others (12, 31, 32). Urban et al. (31, 32) reported that sulbactam alone is highly active against Acinetobacter due to selective affinity to its penicillinbinding proteins, while clavulanate and tazobactam demonstrate considerably less activity. Although both sulbactam and tazobactam alone may exhibit intrinsic activity against some Acinetobacter spp., the difference between them is thought to be related to their relative pharmacokinetics (1, 30 32). Therefore, A/S might be considered for use in treatment when imipenem cannot be used or is contraindicated. Very limited conclusions concerning the potential synergy of P/T with aminoglycosides can be made because of the large number of indeterminate FICs. Unfortunately, there is no means to predict which antimicrobial agent-organism combinations will show synergy to guide empiric therapy, and there may not be a correlation between in vitro synergy and clinical efficacy (2, 19). Therefore, in vitro data must be validated by assessing the clinical performance of combinations of antimicrobial agents before specific recommendations to modify existing treatment guidelines for Acinetobacter infections are possible. ACKNOWLEDGMENTS This work was supported in part by grants from Wyeth-Ayerst Laboratories, Philadelphia, Pa., and Merck and Company, Inc., West Point, Pa. We gratefully acknowledge Yvonne Huang for providing technical support, Julie Mangino for helpful suggestions in selecting the antimicrobial combinations for synergy testing, and Michael Reinke, William Rogers, Edwin Swiatlo, and Thomas Rivers for helpful suggestions regarding the preparation of the manuscript. REFERENCES 1. Allen, D. M., and B. J. Hartman Acinetobacter species, p In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases. Churchill Livingstone, New York, N.Y. 2. Anstey, N. M Use of cefotaxime for treatment of Acinetobacter infections. Clin. Infect. Dis. 15: Bergogne-Berezin, E., M. L. Joly-Guillou, and J. F. Vieu Epidemiology of nosocomial infections due to Acinetobacter calcoaceticus. J. Hosp. Infect. 10: Bouvet, P. J. M., and P. A. D. Grimont Taxonomy of the genus Acinetobacter with the recognition of Acinetobacter baumannii sp. nov. Acinetobacter haemolyticus sp. nov. Acinetobacter johnsonii sp. nov., and Acinetobacter junii sp. nov. and amended descriptions of Acinetobacter calcoaceticus and Acinetobacter lwoffii. Int. J. Syst. Bacteriol. 35: Bouvet, P. J. M., and P. A. D. Grimont Identification and biotyping of clinical isolates of Acinetobacter. Ann. Ińst. Pasteur Microbiol. 138: Bouvet, P. J. M., S. Jeanjean, J.-F. Vieu, and L. Dijkshoorn Species, biotype, and bacteriophage type determinations compared with cell envelope protein profiles for typing Acinetobacter strains. J. Clin. Microbiol. 28: Caillon, J., F. Guerif, L. Raskine, J. Jouanelle, and Y. Xiong Comparative bactericidal activity of imipenem, piperacillin tazobactam, ticarcillin clavulanic acid alone and in combination with amikacin or sulbactam against Acinetobacter baumannii with different resistance phenotypes, abstr. E-101, p In Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C. 8. Chang, S. C., Y. C. Chen, K. T. Luh, and W. C. Hsieh In vitro activities of antimicrobial agents, alone and in combination, against Acinetobacter baumannii isolated from blood. Diagn. Microbiol. Infect. Dis. 23: Chopade, B. A., P. J. Wise, and K. J. Towner Plasmid transfer and behaviour in Acinetobacter calcoaceticus EBF65/65. J. Gen. Microbiol. 131: Crombach, W. H. J., L. Dijkshoorn, M. van Noort-Klaassen, J. Niessen, and G. van Knippenberg-Gordebeke Control of an epidemic spread of a multidrug-resistant strain of Acinetobacter calcoaceticus in a hospital. Intensive Care Med. 85: Devaud, M., F. H. Kayser, and B. Bachi Transposon-mediated multiple antibiotic resistance in Acinetobacter strains. Antimicrob. Agents Chemother. 22: Douboyas, J., L. S. Tzouvelekis, and A. Tsakris In-vitro activity of ampicillin/sulbactam against multi drug-resistant Acinetobacter calcoaceticus var. anitratus clinical isolates. J. Antimicrob. Chemother. 34: Drusano, G. L Human pharmacodynamics of -lactams, aminoglycosides and their combination. Scand. J. Infect. Dis. Suppl. 74: Eliopoulos, G. M., and C. T. Eliopoulos Antibiotic combinations: should they be tested? Clin. Microbiol. Rev. 1: Goldstein, F. W., A. Labigne-Roussel, G. Gerbaud, C. Carlier, E. Collatz, and P. Courvalin Transferable plasmid-mediated antibiotic resistance in Acinetobacter. Plasmid 10: Isenberg, H. D Synergism testing: broth microdilution checkerboard and broth macrodilution methods. In Clinical microbiology procedures manual, vol. 1, p American Society for Microbiology, Washington, D.C. 17. Joly-Guillou, M. L., E. Bergogne-Berezin, and N. Moreau Enzymatic resistance to -lactams and aminoglycosides in Acinetobacter calcoaceticus.j. Antimicrob. Chemother. 20: Joly-Guillou, M. L., E. Bergogne-Berezin, and J. F. Vieu A study of the relationships between antibiotic resistance phenotypes, phage-typing and biotyping of 117 clinical isolates of Acinetobacter sp. J. Hosp. Infect. 16: Klastersky, J., F. Meunier-Carpentier, and J. M. Prevost Significance of antimicrobial synergism for the outcome of gram negative sepsis. Am. J. Med. Sci. 273: Marques, M. B., J. E. Mangino, B. B. Hines, S. A. Moser, and K. B. Waites Investigation of an outbreak of multidrug-resistant Acinetobacter baumannii in a medical intensive care unit, abstr. L-33, p In Abstracts of the 95th General Meeting of the American Society for Microbiology. American Society for Microbiology, Washington, D.C. 21. Martinez-Martinez, L., G. Rodriguez, A. Pascual, A. I. Suarez, and E. J. Perea In vitro activity of several antimicrobial combinations against multiresistant Acinetobacter baumannii, abstr. E-104, p In Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C. 22. Meyers, B. R., P. Wilkinson, M. H. Mendelson, S. Walsh, C. Bournazos, and S. Z. Hirschman Pharmacokinetics of ampicillin-sulbactam in healthy elderly and young volunteers. Antimicrob. Agents Chemother. 35: National Committee for Clinical Laboratory Standards Performance standards for antimicrobial susceptibility testing; fifth informational supplement. NCCLS document M100-S5, vol. 14. National Committee for Clinical Laboratory Standards, Villanova, Pa. 24. Physicians Desk Reference Physicians desk reference, 49th ed. Medical Economics Data Production Co., Montvale, N.J. 25. Rogers, J. D., M. A. P. Meisinger, F. Ferber, G. B. Calandra, J. L. Demetriades, and J. A. Bland Pharmacokinetics of imipenem and cilastatin in volunteers. Rev. Infect. Dis. 7(Suppl. 3):S435 S Scully, B. E., N. Chin, and H. C. Neu Pharmacology of ticarcillin combined with clavulanic acid in humans. Am. J. Med. 79: Seifert, H., R. Baginski, A. Schulze, and G. Pulverer Antimicrobial susceptibility of Acinetobacter species. Antimicrob. Agents Chemother. 37: Sorgel, F., and M. Kinzig The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam. J. Antimicrob. Chemother. 31(Suppl. A): Tilley, P. A., and F. J. Roberts Bacteremia with Acinetobacter species: risk factors and prognosis in different clinical settings. Clin. Infect. Dis. 18: Traub, W. H., and M. Spohr Antimicrobial drug susceptibility of clinical isolates of Acinetobacter species (A. baumannii, A. haemolyticus, genospecies 3, and genospecies 6). Antimicrob. Agents Chemother. 33: Urban, C., E. Go, N. Mariano, B. J. Berger, I. Avraham, D. Rubin, and J. J. Rahal Effect of sulbactam on infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus. J. Infect. Dis. 167: Urban, C., E. Go, N. Mariano, and J. J. Rahal Interaction of sulbactam, clavulanic acid and tazobactam with penicillin-binding proteins of imipenem-resistant and -susceptible Acinetobacter baumannii. FEMS Microbiol. Lett. 125: Vila, J., M. Almela, and M. T. Jimenez de Anta Laboratory investigation of a hospital outbreak caused by two different multiresistant Acinetobacter calcoaceticus subsp. anitratus strains. J. Clin. Microbiol. 27: Vila, J., A. Marcos, F. Marco, S. Abdalla, Y. Vergara, R. Reig, R. Gomez-Lus, and T. Jimenez de Anta In vitro antimicrobial production of -lactamases, aminoglycoside-modifying enzymes, and chloramphenicol acetyltransferase by and susceptibility of clinical isolates of Acinetobacter baumannii. Antimicrob. Agents Chemother. 37: Wang, G., T. S. Whittam, C. M. Berg, and D. E. Berg RAPD (arbitrary primer) PCR is more sensitive than multilocus enzyme electrophoresis for distinguishing bacterial strains. Nucleic Acids Res. 21:
(This work was presented in part at the 18th Annual Meeting of the Surgical Infection Society, 30 April to 2 May 1998, abstr. P18, p. 93.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2000, p. 1035 1040 Vol. 44, No. 4 0066-4804/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. In Vitro Activities of Nontraditional
More information2 0 hr. 2 hr. 4 hr. 8 hr. 10 hr. 12 hr.14 hr. 16 hr. 18 hr. 20 hr. 22 hr. 24 hr. (time)
Key words I μ μ μ μ μ μ μ μ μ μ μ μ μ μ II Fig. 1. Microdilution plate. The dilution step of the antimicrobial agent is prepared in the -well microplate. Serial twofold dilution were prepared according
More informationNational Surveillance of Antimicrobial Resistance in Pseudomonas aeruginosa Isolates Obtained from Intensive Care Unit Patients from 1993 to 2002
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Dec. 2004, p. 4606 4610 Vol. 48, No. 12 0066-4804/04/$08.00 0 DOI: 10.1128/AAC.48.12.4606 4610.2004 Copyright 2004, American Society for Microbiology. All Rights
More informationagainst Clinical Isolates of Gram-Positive Bacteria
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 366-370 Vol. 37, No. 0066-0/93/00366-05$0.00/0 Copyright 993, American Society for Microbiology In Vitro Activity of CP-99,9, a New Fluoroquinolone,
More information2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine
2012 ANTIBIOGRAM Central Zone Former DTHR Sites Department of Pathology and Laboratory Medicine Medically Relevant Pathogens Based on Gram Morphology Gram-negative Bacilli Lactose Fermenters Non-lactose
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationIntroduction to Pharmacokinetics and Pharmacodynamics
Introduction to Pharmacokinetics and Pharmacodynamics Diane M. Cappelletty, Pharm.D. Assistant Professor of Pharmacy Practice Wayne State University August, 2001 Vocabulary Clearance Renal elimination:
More informationPrevalence of Metallo-Beta-Lactamase Producing Pseudomonas aeruginosa and its antibiogram in a tertiary care centre
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 4 Number 9 (2015) pp. 952-956 http://www.ijcmas.com Original Research Article Prevalence of Metallo-Beta-Lactamase
More informationEvaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals
J Vet Diagn Invest :164 168 (1998) Evaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals Susannah K. Hubert, Phouc Dinh Nguyen, Robert D. Walker Abstract.
More informationOutline. Antimicrobial resistance. Antimicrobial resistance in gram negative bacilli. % susceptibility 7/11/2010
Multi-Drug Resistant Organisms Is Combination Therapy the Way to Go? Sutthiporn Pattharachayakul, PharmD Prince of Songkhla University, Thailand Outline Prevalence of anti-microbial resistance in Acinetobacter
More informationOriginal Article. Ratri Hortiwakul, M.Sc.*, Pantip Chayakul, M.D.*, Natnicha Ingviya, B.Sc.**
Original Article In Vitro Activity of Cefminox and Other β-lactam Antibiotics Against Clinical Isolates of Extended- Spectrum-β-lactamase-Producing Klebsiella pneumoniae and Escherichia coli Ratri Hortiwakul,
More informationAcinetobacter species-associated infections and their antibiotic susceptibility profiles in Malaysia.
Biomedical Research 12; 23 (4): 571-575 ISSN 97-938X Scientific Publishers of India Acinetobacter species-associated infections and their antibiotic susceptibility profiles in Malaysia. Nazmul MHM, Jamal
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control as recommended by EUCAST Version 5.0, valid from 015-01-09 This document should be cited as "The
More informationThe Basics: Using CLSI Antimicrobial Susceptibility Testing Standards
The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards Janet A. Hindler, MCLS, MT(ASCP) UCLA Health System Los Angeles, California, USA jhindler@ucla.edu 1 Learning Objectives Describe information
More informationESBL Producers An Increasing Problem: An Overview Of An Underrated Threat
ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat Hicham Ezzat Professor of Microbiology and Immunology Cairo University Introduction 1 Since the 1980s there have been dramatic
More informationTel: Fax:
CONCISE COMMUNICATION Bactericidal activity and synergy studies of BAL,a novel pyrrolidinone--ylidenemethyl cephem,tested against streptococci, enterococci and methicillin-resistant staphylococci L. M.
More informationSepsis is the most common cause of death in
ADDRESSING ANTIMICROBIAL RESISTANCE IN THE INTENSIVE CARE UNIT * John P. Quinn, MD ABSTRACT Two of the more common strategies for optimizing antimicrobial therapy in the intensive care unit (ICU) are antibiotic
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More informationGENERAL NOTES: 2016 site of infection type of organism location of the patient
GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered
More informationMili Rani Saha and Sanya Tahmina Jhora. Department of Microbiology, Sir Salimullah Medical College, Mitford, Dhaka, Bangladesh
Detection of extended spectrum beta-lactamase producing Gram-negative organisms: hospital prevalence and comparison of double disc synergy and E-test methods Mili Rani Saha and Sanya Tahmina Jhora Original
More informationa. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2.
AND QUANTITATIVE PRECISION (SAMPLE UR-01, 2017) Background and Plan of Analysis Sample UR-01 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony
More informationAntimicrobial Susceptibility Testing: Advanced Course
Antimicrobial Susceptibility Testing: Advanced Course Cascade Reporting Cascade Reporting I. Selecting Antimicrobial Agents for Testing and Reporting Selection of the most appropriate antimicrobials to
More informationAntibiotic utilization and Pseudomonas aeruginosa resistance in intensive care units
NEW MICROBIOLOGICA, 34, 291-298, 2011 Antibiotic utilization and Pseudomonas aeruginosa resistance in intensive care units Vladimíra Vojtová 1, Milan Kolář 2, Kristýna Hricová 2, Radek Uvízl 3, Jan Neiser
More informationIntrinsic, implied and default resistance
Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been
More informationDetection and Quantitation of the Etiologic Agents of Ventilator Associated Pneumonia in Endotracheal Tube Aspirates From Patients in Iran
Letter to the Editor Detection and Quantitation of the Etiologic Agents of Ventilator Associated Pneumonia in Endotracheal Tube Aspirates From Patients in Iran Mohammad Rahbar, PhD; Massoud Hajia, PhD
More informationComparative Assessment of b-lactamases Produced by Multidrug Resistant Bacteria
Comparative Assessment of b-lactamases Produced by Multidrug Resistant Bacteria Juhee Ahn Department of Medical Biomaterials Engineering Kangwon National University October 23, 27 Antibiotic Development
More informationDR. MICHAEL A. BORG DIRECTOR OF INFECTION PREVENTION & CONTROL MATER DEI HOSPITAL - MALTA
DR. MICHAEL A. BORG DIRECTOR OF INFECTION PREVENTION & CONTROL MATER DEI HOSPITAL - MALTA The good old days The dread (of) infections that used to rage through the whole communities is muted Their retreat
More informationAntibiotic Susceptibility of Pseudomonas aeruginosa
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, June 1978, p. 979-984 0066-4804/78/0013-0979$02.00/0 Copyright ) 1978 American Society for Microbiology Vol. 13, No. 6 Printed in U.S.A. Effect of Triethylenetetramine
More informationIN VITRO COMBINATION EFFECTS OF NORFLOXACIN, GENTAMICIN, AND Ĉ- LACTAMS ON Ĉ- LACTAM RESISTANT PSEUDOMONAS AERUGINOSA
IN VITRO COMBINATION EFFECTS OF NORFLOXACIN, GENTAMICIN, AND Ĉ- LACTAMS ON Ĉ- LACTAM RESISTANT PSEUDOMONAS AERUGINOSA YONGYUTH JITTAROPAS NAOTO 1), RIKITOMI 2), and Kaizo MATSUMOTO 2) 1) Department of
More informationEXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING
EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING CHN61: EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING 1.1 Introduction A common mechanism of bacterial resistance to beta-lactam antibiotics is the production
More informationPerformance Information. Vet use only
Performance Information Vet use only Performance of plates read manually was measured in three sites. Each centre tested Enterobacteriaceae, streptococci, staphylococci and pseudomonas-like organisms.
More informationUnderstanding the Hospital Antibiogram
Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital
More informationETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections
ETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections Robin Isaacs Chief Medical Officer, Entasis Therapeutics Dr. Isaacs is a full-time employee of Entasis Therapeutics.
More informationMICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC
MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical
More informationWhat does multiresistance actually mean? Yohei Doi, MD, PhD University of Pittsburgh
What does multiresistance actually mean? Yohei Doi, MD, PhD University of Pittsburgh Disclosures Merck Research grant Clinical context of multiresistance Resistance to more classes of agents Less options
More informationPrevalence of Extended Spectrum Beta- Lactamase Producers among Various Clinical Samples in a Tertiary Care Hospital: Kurnool District, India
International Journal of Current Microbiology and Applied Sciences ISSN: 319-77 Volume Number (17) pp. 57-3 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/1.5/ijcmas.17..31
More informationAntimicrobial Susceptibility Testing: The Basics
Antimicrobial Susceptibility Testing: The Basics Susan E. Sharp, Ph.D., DABMM, FAAM Director, Airport Way Regional Laboratory Director, Regional Microbiology and Molecular Infectious Diseases Laboratories
More informationPharmacological Evaluation of Amikacin in Neonates
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, JUlY 1975, p. 86-90 Copyright 0 1975 American Society for Microbiology Vol. 8, No. 1 Printed in U.SA. Pharmacological Evaluation of Amikacin in Neonates JORGE B.
More informationEvaluation of the AutoMicrobic System for Susceptibility Testing of Aminoglycosides and Gram-Negative Bacilli
JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 1987, p. 546-550 0095-1137/87/030546-05$02.00/0 Copyright C 1987, American Society for Microbiology Vol. 25, No. 3 Evaluation of the AutoMicrobic System for Susceptibility
More informationDetecting / Reporting Resistance in Nonfastidious GNR Part #2. Janet A. Hindler, MCLS MT(ASCP)
Detecting / Reporting Resistance in Nonfastidious GNR Part #2 Janet A. Hindler, MCLS MT(ASCP) Methods Described in CLSI M100-S21 for Testing non-enterobacteriaceae Organism Disk Diffusion MIC P. aeruginosa
More informationBrief reports. Heat stability of the antimicrobial activity of sixty-two antibacterial agents
Journal of Antimicrobial Chemotherapy (5) 35, -5 Brief reports Heat stability of the antimicrobial activity of sixty-two antibacterial agents Walter H. Traub and Birgit Leonhard Institut fur Medizinische
More informationAn evaluation of the susceptibility patterns of Gram-negative organisms isolated in cancer centres with aminoglycoside usage
Journal of Antimicrobial Chemotherapy (1991) 27, Suppl. C, 1-7 An evaluation of the susceptibility patterns of Gram-negative organisms isolated in cancer centres with aminoglycoside usage J. J. Muscato",
More informationMichael T. Sweeney* and Gary E. Zurenko. Infectious Diseases Biology, Pharmacia Corporation, Kalamazoo, Michigan 49007
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, June 2003, p. 1902 1906 Vol. 47, No. 6 0066-4804/03/$08.00 0 DOI: 10.1128/AAC.47.6.1902 1906.2003 Copyright 2003, American Society for Microbiology. All Rights Reserved.
More informationReceived: February 29, 2008 Revised: July 22, 2008 Accepted: August 4, 2008
J Microbiol Immunol Infect. 29;42:317-323 In vitro susceptibilities of aerobic and facultative anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections at a medical center
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Antibiotic Susceptibility Pattern of Pseudomonas Aeruginosa Isolated From Various Clinical
More informationMulticenter Study of In Vitro Susceptibility of the Bacteroides fragilis Group, 1995 to 1996, with Comparison of Resistance Trends from 1990 to 1996
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Oct. 1999, p. 2417 2422 Vol. 43, No. 10 0066-4804/99/$04.00 0 Copyright 1999, American Society for Microbiology. All Rights Reserved. Multicenter Study of In Vitro
More informationAvailable online at ISSN No:
Available online at www.ijmrhs.com ISSN No: 2319-5886 International Journal of Medical Research & Health Sciences, 2017, 6(4): 36-42 Comparative Evaluation of In-Vitro Doripenem Susceptibility with Other
More informationInfluence of ph on Adaptive Resistance of Pseudomonas aeruginosa to Aminoglycosides and Their Postantibiotic Effects
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Jan. 1996, p. 35 39 Vol. 40, No. 1 0066-4804/96/$04.00 0 Copyright 1996, American Society for Microbiology Influence of ph on Adaptive Resistance of Pseudomonas aeruginosa
More informationExtremely Drug-resistant organisms: Synergy Testing
Extremely Drug-resistant organisms: Synergy Testing Background Acinetobacter baumannii& Pseudomonas aeruginosa Emerging Gram-negative bacilli Part of the ESKAPE group of organisms 1 Enterococcus faecium
More informationPILOT STUDY OF THE ANTIMICROBIAL SUSCEPTIBILITY OF SHIGELLA IN NEW ZEALAND IN 1996
PILOT STUDY OF THE ANTIMICROBIAL SUSCEPTIBILITY OF SHIGELLA IN NEW ZEALAND IN 996 November 996 by Maggie Brett Antibiotic Reference Laboratory ESR Communicable Disease Centre Porirua CONTENTS Page SUMMARY
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST Version 8.0, valid from 018-01-01
More informationAPPENDIX III - DOUBLE DISK TEST FOR ESBL
Policy # MI\ANTI\04\03\v03 Page 1 of 5 Section: Antimicrobial Susceptibility Testing Manual Subject Title: Appendix III - Double Disk Test for ESBL Issued by: LABORATORY MANAGER Original Date: January
More informationJanuary 2014 Vol. 34 No. 1
January 2014 Vol. 34 No. 1. and Minimum Inhibitory Concentration (MIC) Interpretive Standards for Testing Conditions Medium: diffusion: Mueller-Hinton agar (MHA) Broth dilution: cation-adjusted Mueller-Hinton
More informationUpdate on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia. Po-Ren Hsueh. National Taiwan University Hospital
Update on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia Po-Ren Hsueh National Taiwan University Hospital Ventilator-associated Pneumonia Microbiological Report Sputum from a
More informationRoutine internal quality control as recommended by EUCAST Version 3.1, valid from
Routine internal quality control as recommended by EUCAST Version.1, valid from 01-01-01 Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus
More informationVersion 1.01 (01/10/2016)
CHN58: ANTIMICROBIAL SUSCEPTIBILITY TESTING (CLSI) 1.0 PURPOSE / INTRODUCTION: 1.1 Introduction Antimicrobial susceptibility tests are performed in order to determine whether a pathogen is likely to be
More informationDetection of Inducible AmpC β-lactamase-producing Gram-Negative Bacteria in a Teaching Tertiary Care Hospital in North India
Original Article Vol. 25 No. 3 Ampc β-lactamase Production in Gram-Negative Bacilli:-Chaudhary U, et al. 129 Detection of Inducible AmpC β-lactamase-producing Gram-Negative Bacteria in a Teaching Tertiary
More informationJanuary 2014 Vol. 34 No. 1
January 2014 Vol. 34 No. 1. and Minimal Inhibitory Concentration (MIC) Interpretive Standards for Testing Conditions Medium: diffusion: Mueller-Hinton agar (MHA) roth dilution: cation-adjusted Mueller-Hinton
More informationHelp with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST
Help with moving disc diffusion methods from BSAC to EUCAST This document sets out the main differences between the BSAC and EUCAST disc diffusion methods with specific emphasis on preparation prior to
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXIII NUMBER 1 July 2008 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell, SM (ASCP), Marti Roe SM (ASCP), Ann-Christine Nyquist MD, MSPH Are the bugs winning? The 2007
More information2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services
2015 Antibiogram Red Deer Regional Hospital Central Zone Alberta Health Services Introduction. This antibiogram is a cumulative report of the antimicrobial susceptibility rates of common microbial pathogens
More informationEUCAST recommended strains for internal quality control
EUCAST recommended strains for internal quality control Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus influenzae ATCC 59 ATCC
More informationEvaluation of MicroScan MIC Panels for Detection of
JOURNAL OF CLINICAL MICROBIOLOGY, May 1988, p. 816-820 Vol. 26, No. 5 0095-1137/88/050816-05$02.00/0 Copyright 1988, American Society for Microbiology Evaluation of MicroScan MIC Panels for Detection of
More informationSynergy of Daptomycin with Oxacillin and Other -Lactams against Methicillin-Resistant Staphylococcus aureus
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 2004, p. 2871 2875 Vol. 48, No. 8 0066-4804/04/$08.00 0 DOI: 10.1128/AAC.48.8.2871 2875.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved.
More informationAminoglycoside-resistant enterococci
Aminoglycoside-resistant enterococci M. J. BASKER, B. SLOCOMBE, AND R. SUTHERLAND From Beecham Pharmaceuticals Research Division, Brockham Park, Betchworth, Surrey J. clin. Path., 1977, 30, 375-380 SUMMARY
More informationDefining Extended Spectrum b-lactamases: Implications of Minimum Inhibitory Concentration- Based Screening Versus Clavulanate Confirmation Testing
Infect Dis Ther (2015) 4:513 518 DOI 10.1007/s40121-015-0094-6 BRIEF REPORT Defining Extended Spectrum b-lactamases: Implications of Minimum Inhibitory Concentration- Based Screening Versus Clavulanate
More informationAntimicrobial Susceptibility Patterns
Antimicrobial Susceptibility Patterns KNH SURGERY Department Masika M.M. Department of Medical Microbiology, UoN Medicines & Therapeutics Committee, KNH Outline Methodology Overall KNH data Surgery department
More informationMDR Acinetobacter baumannii. Has the post antibiotic era arrived? Dr. Michael A. Borg Infection Control Dept Mater Dei Hospital Malta
MDR Acinetobacter baumannii Has the post antibiotic era arrived? Dr. Michael A. Borg Infection Control Dept Mater Dei Hospital Malta 1 The Armageddon recipe Transmissible organism with prolonged environmental
More informationThe β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018
The β- Lactam Antibiotics Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 Penicillins. Cephalosporins. Carbapenems. Monobactams. The β- Lactam Antibiotics 2 3 How
More informationBrief reports. Decreased susceptibility to imipenem among penicillin-resistant Streptococcus pneumoniae
Journal of Antimicrobial Chemotherapy (1997) 40, 105 108 Brief reports JAC Decreased susceptibility to imipenem among penicillin-resistant Streptococcus pneumoniae Andreas Pikis a *, Jacob A. Donkersloot
More informationOther Beta - lactam Antibiotics
Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics
More informationESBL- and carbapenemase-producing microorganisms; state of the art. Laurent POIREL
ESBL- and carbapenemase-producing microorganisms; state of the art Laurent POIREL Medical and Molecular Microbiology Unit Dept of Medicine University of Fribourg Switzerland INSERM U914 «Emerging Resistance
More informationDETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY*
44 DETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY* AUTHOR: Cecilia C. Maramba-Lazarte, MD, MScID University of the Philippines College of Medicine-Philippine
More information2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2016 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
More informationIn Vitro Antimicrobial Activity of CP-99,219, a Novel Azabicyclo-Naphthyridone
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 39-353 0066-0/93/0039-05$0.00/0 Copyright 993, American Society for Microbiology Vol. 37, No. In Vitro Antimicrobial Activity of, a Novel Azabicyclo-Naphthyridone
More informationOriginal Article. Suthan Srisangkaew, M.D. Malai Vorachit, D.Sc.
Original Article Vol. 21 No.1 The optimum agent for ESBL screening and confirmatory tests:- Srisangkaew S & Vorachit M. 1 The Optimum Agent for Screening and Confirmatory Tests for Extended-Spectrum Beta-Lactamases
More information2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2017 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
More informationReceived 21 June 2002/Returned for modification 23 July 2002/Accepted 24 September 2002
JOURNAL OF CLINICAL MICROBIOLOGY, Dec. 2002, p. 4571 4575 Vol. 40, No. 12 0095-1137/02/$04.00 0 DOI: 10.1128/JCM.40.12.4571 4575.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved.
More informationIn vitro activity of gatifloxacin alone and in combination with cefepime, meropenem, piperacillin and gentamicin against multidrug-resistant organisms
Advance Access published April 14, 2003 Journal of Antimicrobial Chemotherapy DOI: 10.1093/jac/dkg238 In vitro activity of gatifloxacin alone and in combination with cefepime, meropenem, piperacillin and
More informationConcise Antibiogram Toolkit Background
Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions
More informationEvaluation of the BIOGRAM Antimicrobial Susceptibility Test System
JOURNAL OF CLINICAL MICROBIOLOGY, Nov. 1985, p. 793-798 0095-1137/85/110793-06$02.00/0 Copyright 1985, American Society for Microbiology Vol. 22, No. 5 Evaluation of the BIOGRAM Antimicrobial Susceptibility
More informationHelen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory
METHODS USED IN NEW ZEALAND DIAGNOSTIC LABORATORIES TO IDENTIFY AND REPORT EXTENDED-SPECTRUM β-lactamase- PRODUCING ENTEROBACTERIACEAE by Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory
More informationPrinciples and Practice of Antimicrobial Susceptibility Testing. Microbiology Technical Workshop 25 th September 2013
Principles and Practice of Antimicrobial Susceptibility Testing Microbiology Technical Workshop 25 th September 2013 Scope History Why Perform Antimicrobial Susceptibility Testing? How to Perform an Antimicrobial
More informationBurton's Microbiology for the Health Sciences. Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents
Burton's Microbiology for the Health Sciences Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents Chapter 9 Outline Introduction Characteristics of an Ideal Antimicrobial Agent How
More informationComparative Activity of Netilmicin, Gentamicin, Amikacin, and Tobramycin Against Pseudomonas aeruginosa and Enterobacteriaceae
ANTIMICROBIAL AGzNTS AND CHEMOTHERAPY, Oct. 1976, P. 592-597 Copyright 1976 American Society for Microbiology Vol. 1, No. 4 Printed in U.S.A. Comparative Activity of Netilmicin, Gentamicin, Amikacin, and
More informationThere are two international organisations that set up guidelines and interpretive breakpoints for bacteriology and susceptibility
ANTIMICROBIAL SUSCEPTIBILITY TESTING ON MILK SAMPLES Method and guidelines There are two international organisations that set up guidelines and interpretive breakpoints for bacteriology and susceptibility
More informationInt.J.Curr.Microbiol.App.Sci (2017) 6(3):
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 3 (2017) pp. 891-895 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.603.104
More information2009 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Childrens Hospital
2009 ANTIBIOGRAM University of Alberta Hospital and the Stollery Childrens Hospital Division of Medical Microbiology Department of Laboratory Medicine and Pathology 2 Table of Contents Page Introduction.....
More informationIn Vitro Activity of Netilmicin, Gentamicin, and Amikacin
ANTIMICROBIAL AGzNTS AND CHEMOTHERAPY, Jan. 1977, p. 126-131 Copyright X 1977 American Society for Microbiology Vol. 11, No. 1 Printed in U.S.A. In Vitro Activity of Netilmicin, Gentamicin, and Amikacin
More informationUDC: : :579.22/ :615.28
www.imiamn.org.ua /journal.htm 8 UDC: 6.33:61.017.1:579./.841.9:6.8 SUBSTANTIATION OF OVERCOMING OF ANTIBIOTIC RESISTANCE IN ACINETOBACTER BAUMANNII CLINICAL STRAINS BY USAGE OF DECAMETHOXINUM Nazarchuk
More informationChristiane Gaudreau* and Huguette Gilbert
Journal of Antimicrobial Chemotherapy (1997) 39, 707 712 JAC Comparison of disc diffusion and agar dilution methods for antibiotic susceptibility testing of Campylobacter jejuni subsp. jejuni and Campylobacter
More informationTitle: N-Acetylcysteine (NAC) Mediated Modulation of Bacterial Antibiotic
AAC Accepts, published online ahead of print on June 00 Antimicrob. Agents Chemother. doi:0./aac.0070-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationThe First Report of CMY, AAC(6')-Ib and 16S rrna Methylase Genes among Pseudomonas aeruginosa Isolates from Iran
1 2 The First Report of CMY, AAC(6')-Ib and 16S rrna Methylase Genes among Pseudomonas aeruginosa Isolates from Iran Sedigheh Rafiei Tabatabaei, MD, MPH Associate Professor of Pediatric Infectious Diseases
More information2010 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Children s Hospital
2010 ANTIBIOGRAM University of Alberta Hospital and the Stollery Children s Hospital Medical Microbiology Department of Laboratory Medicine and Pathology Table of Contents Page Introduction..... 2 Antibiogram
More informationOPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS
HTIDE CONFERENCE 2018 OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS FEDERICO PEA INSTITUTE OF CLINICAL PHARMACOLOGY DEPARTMENT OF MEDICINE, UNIVERSITY OF UDINE, ITALY SANTA
More informationAntibiotic Updates: Part II
Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More informationJAC Bactericidal index: a new way to assess quinolone bactericidal activity in vitro
Journal of Antimicrobial Chemotherapy (1997) 39, 713 717 JAC Bactericidal index: a new way to assess quinolone bactericidal activity in vitro Ian Morrissey* Department of Biosciences, Division of Biochemistry
More informationIn Vitro Activities of Tulathromycin and Ceftiofur Combined with Other Antimicrobial Agents Using Bovine Pasteurella multocida
In Vitro Activities of Tulathromycin and Ceftiofur Combined with Other Antimicrobial Agents Using Bovine Pasteurella multocida and Mannheimia haemolytica Isolates* Michael T. Sweeney, MS Gordon W. Brumbaugh,
More informationPrinciples of Antimicrobial Therapy
Principles of Antimicrobial Therapy Doo Ryeon Chung, MD, PhD Professor of Medicine, Division of Infectious Diseases Director, Infection Control Office SUNGKYUNKWAN UNIVERSITY SCHOOL OF MEDICINE CASE 1
More informationDetection of Methicillin Resistant Strains of Staphylococcus aureus Using Phenotypic and Genotypic Methods in a Tertiary Care Hospital
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 7 (2017) pp. 4008-4014 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.607.415
More information